EUCTR2007-003331-23-ES进行中（未招募）不适用
n estudio aleatorizado, controlado con placebo, doble ciego, de seis meses de duración para investigar la seguridad y la tolerabilidad de deferiprona en pacientes con ataxia de Friedreich.A six-month double-blind, randomized, placebo-controlled study investigating the safety and tolerability of deferiprone in participants with Friedreich's ataxia. - Not applicable
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •INCLUSION CRITERIA
- •1. Diagnosis of FRDA, with confirmed mutation (excludes point mutation) in the frataxin (FXN) gene and GAA repeats ? 400 on the shorter allele.
- •2. Males or females aged 7 to 35 years
- •3. No exposure to idebenone, coenzyme Q10, vitamin C, vitamin E or other antioxidants as a supplement or as a drug therapy for a period of at least one month prior to start of treatment and during the study.
- •4. Neurological testing: A FARS score >20 and <85 at Screening and Baseline.
- •5. Female subjects of childbearing potential must have a negative pregnancy test at Baseline. In addition, a female subject must confirm that during the study and within 30 days following the completion of the study or early termination she:
- •? will use an effective method of contraception, OR
- •? has had a tubal ligation (supporting evidence required), OR
- •? has had a hysterectomy (supporting evidence required), OR
- •? participates in a non-heterosexual lifestyle, OR
- •? indicates her only male sexual partner has been sterilized (supporting evidence required).
- •Effective methods of contraception include oral contraceptives, intrauterine devices (IUDs) (in place for at least 3 months prior to first dose), diaphragm or condom, providing they are used with contraceptive foam or cream, or abstinence from sexual intercourse. Supporting evidence for sterilization consists of a surgical report or letter from the family physician.
- •6. If the subject is a heterosexual, sexually-active male, he confirms that he and/or his female partner will use an effective method of contraception for the length of the trial and for 30 days following completion of the study or early termination. Effective methods of contraception for males include condoms or sterilization or abstinence from sexual intercourse.
- •7. Signed and witnessed written informed consent/assent obtained prior to the first study intervention, as well as the ability to adhere to study restrictions, appointments and evaluation schedule.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •EXCLUSION CRITERIA:
- •1. Iron deficiency defined as ferritin levels below the reference range for age- and sex-matched controls
- •2. Unable to complete T25FW AND with score > 5 minutes in the 9HPT. (Subjects who can complete T25FW or with a score ? 5 minutes in the 9HPT will be allowed to enrol if the score has not doubled compared to screening).
- •3. Abnormal ALT, greater than 2.0 times the upper limit of normal on two consecutive assessments.
- •4. Serum creatinine outside the normal reference range.
- •5. History or evidence of neutropenia/agranulocytosis defined by an absolute neutrophil count (ANC) < 1.5 x 10E9/L or thrombocytopenia defined by a platelet count <150 x 10E9/L.
- •6. Refusal to participate in screening procedures or unable to participate in screening procedures or unable to comply with the requirements of the protocol.
- •7. Receiving any investigational drug products or having received any investigational product within 30 days prior to enrolment into this study.
- •8. Subjects who have previously taken deferiprone.
- •9. Subjects who, in the opinion of the Investigator, represent poor medical, psychological or psychiatric risks, and for whom participation in an investigational trial would be unwise.
- •10. Pregnant, breastfeeding or planning to become pregnant during the study period.
- •11. History of malignancy.
- •12. History of alcohol or drug abuse.
- •13. Investigators, site personnel directly affiliated with this study and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.
- •14. Hypersensitivity to the active substance (deferiprone) or any of the excipients in the oral solution.
- •15. QT interval greater than 450 ms at Baseline.
研究者
相似试验
进行中（未招募）
不适用
Estudio aleatorizado, controlado con placebo, para evaluar la seguridad y eficacia de añadir tocilizumab (TCZ) a metotrexato (MTX) frente al cambio a TCZ (controlado con placebo), con la posibilidad de añadir otros fármacos antirreumáticos modificadores de la enfermedad (FAMEs), en pacientes con artritis reumatoide activa que tienen una respuesta inadecuada al tratamiento previo con MTX.Artritis reumatoideMedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2008-001847-20-ESF Hoffmann-La Roche Ltd470
进行中（未招募）
不适用
Estudio aleatorizado, controlado con placebo, internacional, multicéntrico, doble ciego, de confirmación de dosis, para evaluar la seguridad y la eficacia de la crema ASF-1096 0,25%, 0,5% y 1% y placebo administradas dos veces al día en el tratamiento de las lesiones cutáneas del lupus eritematosoRandomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions - ASF-1096-301EUCTR2007-004635-29-ESAstion Pharma A/S140
进行中（未招募）
1 期
Estudio aleatorizado, controlado con placebo, a doble ciego, de 24 semanas de duración para evaluar la eficacia y seguridad de flibanserina en dosis de 50 mg /día y 100 mg /día en mujeres premenopáusicas europeas con trastorno de deseo sexual hipoactivo.A Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in premenopausal European Women With Hypoactive Sexual Desire Disorder - OrchidEUCTR2007-000032-68-ESBoehringer Ingelheim España, S.A.900
进行中（未招募）
不适用
Estudio clínico controlado con placebo, aleatorizado, de fase II, para evaluar la inmunogenicidad y la toxicidad de dos patrones de inducción-refuerzo complementarios con el ALVAC-VIH vCP1452 en pacientes con infección crónica del VIHInfección por el VIHClassification code 10008919EUCTR2004-001525-21-ESORVACS, Objectif Recherche Vaccin SIDA60
进行中（未招募）
1 期
Ensayo clínico aleatorizado, controlado con placebo, en fase III, para evaluar la seguridad y la eficacia de odanacatib (MK-0822) en cuanto a la reducción del riesgo de fractura en mujeres posmenopáusicas con osteoporosis tratadas con vitamina D y calcio.A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of MK-0822 to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and CalciumOsteoporosis postmenopaúsicaPostmenopausal OsteoporosisMedDRA version: 9.1Level: LLTClassification code 10031285Term: Osteoporosis postmenopausalEUCTR2007-002693-66-ESMerck & Co., Inc.16,300